needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth
in different ways. Some block the ability of tumor cells to grow and spread. Others find
tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may
also block the growth of the tumor by blocking blood flow to the tumor. It is not yet known
whether bevacizumab together with dasatinib are more effective than a placebo in treating
patients with recurrent or progressive high-grade glioma or glioblastoma multiforme.
PURPOSE: This randomized phase I/II trial (Phase I completed) is studying the side effects
and best dose of dasatinib when given together with bevacizumab and to see how well it works
compared to placebo in treating patients with recurrent or progressive high-grade glioma or
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
- Cancer Help Line: (800) 639-6918
- Email: email@example.com
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.